Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 1.00 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.57 |
| ▸ | PYGL | P06737 | 9/20 | 0.53 |
| ▸ | PYGM | P11217 | 6/20 | 0.53 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710296 | 1.00 | SMYD3 (1.00) | SMYD3MLLT1PYGLPYGMF7 | |
| SCHEMBL11888212 | 0.88 | SMYD3 (0.79) | SMYD3MLLT1PYGLPYGMF7 | |
| SCHEMBL763943 | 0.87 | SMYD3 (0.77) | SMYD3MLLT1PYGLF7F3 | |
| SCHEMBL12101155 | 0.86 | SMYD3 (0.76) | SMYD3MLLT1PYGLPYGMF7 | |
| SCHEMBL30578672 | 0.86 | SMYD3 (0.76) | SMYD3MLLT1PYGLPYGMF7 | |
| SCHEMBL11960283 | 0.85 | SMYD3 (0.74) | SMYD3MLLT1PYGLPYGMHRH4 | |
| SCHEMBL12670484 | 0.85 | SMYD3 (0.74) | SMYD3MLLT1PYGLPYGMHRH4 | |
| SCHEMBL21490044 | 0.85 | MLLT1 (0.79) | SMYD3MLLT1PYGLPYGMMEN1 | |
| SCHEMBL19710025 | 0.85 | MLLT1 (0.79) | SMYD3MLLT1PYGLPYGMMEN1 | |
| SCHEMBL21490005 | 0.85 | SMYD3 (1.00) | SMYD3MLLT1PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | claimed |
| CN-115028619-A | SMYD inhibitors | EPIZYME股份有限公司 | 2022-09-09 | — | — | CN | claimed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885MLLT1 888/4885PYGL 2466/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885MLLT1 1192/4885PYGL 2678/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885MLLT1 895/4885PYGL 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.